Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Bupivacaine for Pain After Thoracoscopic Lobectomy
NCT06569953Phase 4Recruiting
- Sponsor
- The 2nd Affiliated Hospital of Chongqing Medical University
- Start
- Aug 2024
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of liposomal bupivacaine in postoperative pain (2 arms), sponsored by The 2nd Affiliated Hospital of Chongqing Medical University. Primary endpoints: Area under the movement-evoked pain intensity-time curve and The incidence of chronic postoperative pain at 90 days. Started Aug 2024; status: recruiting.
02
Drugs
liposomal bupivacaine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT06569953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06569953.